Rotavirus vaccines against diarrhoeal disease

[1]  X. Pang,et al.  Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis , 1997, The Lancet.

[2]  A. Kapikian,et al.  Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. , 1997, The New England journal of medicine.

[3]  M. Rao,et al.  Field trial of a locally produced, killed, oral cholera vaccine in Vietnam , 1997, The Lancet.

[4]  R. Glass,et al.  Rotavirus infection in infants as protection against subsequent infections. , 1996, The New England journal of medicine.

[5]  M. Pichichero,et al.  The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. , 1996, The Journal of infectious diseases.

[6]  T. Vesikari,et al.  Review of rotavirus vaccine trials in Finland. , 1996, The Journal of infectious diseases.

[7]  R. Chanock,et al.  Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. , 1996, The Journal of infectious diseases.

[8]  H. Greenberg,et al.  Molecular determinants of immunity and pathogenicity of rotavirus infection in the mouse model. , 1996, The Journal of infectious diseases.

[9]  H. Greenberg,et al.  Protection against rotavirus infections by DNA vaccination. , 1996, The Journal of infectious diseases.

[10]  C. Farrington,et al.  Hospital admissions attributable to rotavirus infection in England and Wales. , 1996, The Journal of infectious diseases.

[11]  R. Ward.  Mechanisms of protection against rotavirus in humans and mice. , 1996, The Journal of infectious diseases.

[12]  P. Offit.  Host factors associated with protection against rotavirus disease: the skies are clearing. , 1996, The Journal of infectious diseases.

[13]  M. Estes,et al.  Virus-like particles as a rotavirus subunit vaccine. , 1996, The Journal of infectious diseases.

[14]  R. Black,et al.  Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. , 1996, The Journal of infectious diseases.

[15]  R. Glass,et al.  Safety and Efficacy of High-dose Rhesus-Human Reassortant Rotavirus Vaccines-Report of the National Multicenter Trial , 1996, Pediatrics.

[16]  H. Greenberg,et al.  Protective Effect of Rotavirus VP6-Specific IgA Monoclonal Antibodies That Lack Neutralizing Activity , 1996, Science.

[17]  M. Pichichero,et al.  WC3 reassortant vaccines in children. , 1996, Archives of virology. Supplementum.

[18]  A. Linhares,et al.  Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belém, Brazil. , 1996, Bulletin of the World Health Organization.

[19]  R. Glass,et al.  Evaluation of Rhesus Rotavirus Monovalent and Tetravalent Reassortant Vaccines in US Children , 1995 .

[20]  R. Glass,et al.  Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. , 1995, JAMA.

[21]  D. Bernstein,et al.  Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines , 1995 .

[22]  J. Holmgren,et al.  Oral vaccines against cholera and enterotoxigenic Escherichia coli diarrhea. , 1995, Advances in experimental medicine and biology.

[23]  M. Levine,et al.  Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. , 1995, Vaccine.

[24]  E. C. Beuvery,et al.  Simultaneous administration of oral rhesus-human reassortant tetravalent (RRV-TV) rotavirus vaccine and oral poliovirus vaccine (OPV) in Thai infants. , 1995, Vaccine.

[25]  M. Estes,et al.  Anti-rotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections. , 1994, The Journal of infectious diseases.

[26]  R. Glass,et al.  Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. , 1993, The Journal of infectious diseases.

[27]  R. Glass,et al.  The magnitude of the global problem of diarrhoeal disease: a ten-year update. , 1992, Bulletin of the World Health Organization.

[28]  M. Georges-Courbot,et al.  Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. , 1991, Research in virology.

[29]  M. Rennels,et al.  An efficacy trial of the rhesus rotavirus vaccine in Maryland. The Clinical Study Group. , 1990, American journal of diseases of children.

[30]  R. Glass,et al.  Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. , 1989, The Journal of infectious diseases.

[31]  R. Black,et al.  Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. , 1989, The Journal of infectious diseases.

[32]  S. Plotkin,et al.  Protective Effect of WC3 Vaccine Against Rotavirus Diarrhea in Infants During a Predominantly Serotype 1 Rotavirus Season , 1988, The Journal of infectious diseases.

[33]  M. Pichichero,et al.  Field trial of rhesus rotavirus vaccine in infants. , 1988, The Pediatric infectious disease journal.

[34]  B. Biryahwaho.  TRIAL OF AN ATTENUATED BOVINE ROTAVIRUS VACCINE (RIT 4237) , 1987, The Lancet.

[35]  E. Norrby,et al.  Immune response to rotavirus polypeptides after vaccination with heterologous rotavirus vaccines (RIT 4237, RRV-1). , 1987, The Journal of general virology.

[36]  P. Byass,et al.  TRIAL OF AN ATTENUATED BOVINE ROTAVIRUS VACCINE (RIT 4237) IN GAMBIAN INFANTS , 1987, The Lancet.

[37]  G. Zissis,et al.  FAILURE OF LIVE, ATTENUATED ORAL ROTAVIRUS VACCINE , 1986, The Lancet.

[38]  G. Zissis,et al.  A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. , 1986, The Journal of infectious diseases.

[39]  R. Glass,et al.  Rotavirus: the major etiologic agent of severe infantile diarrhea may be controllable by a "Jennerian" approach to vaccination. , 1986, The Journal of infectious diseases.

[40]  R. Feachem,et al.  Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. , 1985, Bulletin of the World Health Organization.

[41]  G. Zissis,et al.  PROTECTION OF INFANTS AGAINST ROTAVIRUS DIARRHOEA BY RIT 4237 ATTENUATED BOVINE ROTAVIRUS STRAIN VACCINE , 1984, The Lancet.

[42]  G. Zissis,et al.  Protection studies in colostrum-deprived piglets of a bovine rotavirus vaccine candidate using human rotavirus strains for challenge. , 1983, The Journal of infectious diseases.

[43]  G. Zissis,et al.  IMMUNOGENICITY AND SAFETY OF LIVE ORAL ATTENUATED BOVINE ROTAVIRUS VACCINE STRAIN RIT 4237 IN ADULTS AND YOUNG CHILDREN , 1983, The Lancet.

[44]  G. Barnes,et al.  Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. , 1983, The New England journal of medicine.

[45]  B. Lozoff,et al.  Letter: Medical control over labour. , 1975, Lancet.

[46]  R. Elliott.  WRINKLING OF SKIN IN CYSTIC FIBROSIS , 1974 .